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Abstract: Programmed death ligand 1 (PD-L1) is expressed by 20% to 57% of systemic diffuse large
B cell lymphomas (DLBCLs). PD-L1 expression in primary cutaneous DLBCL (pcDLBCL) has not
been studied so far. Sixteen paraffin-embedded tissue samples of pcDLBCL (13 leg type [LT], 3 others
[OT]) were investigated for PD-1, PD-L1, and CD33 expression and the cellular composition of the
tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs) and tumor-associated
macrophages. Membrane-bound PD-L1 expression by the tumor cells was observed in all samples, albeit
to a variable extent (19.9%). As expected, most DLBCL-LT (10 cases) were classified as activated B
cell like type, with a higher PD-L1 score (21.9%) compared with that of the germinal center B cell like
type (7.7%). The surrounding infiltrate consisted predominately of CD163(+) M2 rather than CD68(+)
macrophages (CD68:CD163=1:4 to 6). Moreover, a considerable proportion of CD33(+) MDSCs with
PD-L1 coexpression was admixed. Tumor cells expressed CD33 to variable degrees (2% to 60%). The
number of MDSCs or M2 macrophages did not correlate with pcDLBCL subtypes LT or OT. T cells
were only a minor component of the tumor microenvironment. We propose that PD-L1(+) tumor cells
and PD-L1(+) MDSCs shield the tumor against PD-1(+) tumor-infiltrating lymphocytes, consequently
leading to inhibition and diminution of tumor-infiltrating lymphocytes. Moreover, we found a polarization
to M2 macrophages, which may contribute to the poor prognosis of DLBCL patients. Thus, targeting
of tumor cells and MDSCs using anti-PD-1/anti-PD-L1 or anti-CD33 antibodies might be a worthwhile
new approach to treat this aggressive form of cutaneous B-cell lymphoma.
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Abstract: Programmed death ligand 1 (PD-L1) is expressed by
20% to 57% of systemic diﬀuse large B cell lymphomas
(DLBCLs). PD-L1 expression in primary cutaneous DLBCL
(pcDLBCL) has not been studied so far. Sixteen paraﬃn-
embedded tissue samples of pcDLBCL (13 leg type [LT], 3
others [OT]) were investigated for PD-1, PD-L1, and CD33
expression and the cellular composition of the tumor micro-
environment, focusing on myeloid-derived suppressor cells
(MDSCs) and tumor-associated macrophages. Membrane-
bound PD-L1 expression by the tumor cells was observed in
all samples, albeit to a variable extent (19.9%). As expected,
most DLBCL-LT (10 cases) were classiﬁed as activated B cell
like type, with a higher PD-L1 score (21.9%) compared with
that of the germinal center B cell like type (7.7%). The sur-
rounding inﬁltrate consisted predominately of CD163(+) M2
rather than CD68(+) macrophages (CD68:CD163=1:4 to 6).
Moreover, a considerable proportion of CD33(+) MDSCs with
PD-L1 coexpression was admixed. Tumor cells expressed CD33
to variable degrees (2% to 60%). The number of MDSCs or M2
macrophages did not correlate with pcDLBCL subtypes LT or
OT. T cells were only a minor component of the tumor micro-
environment. We propose that PD-L1(+) tumor cells and PD-
L1(+) MDSCs shield the tumor against PD-1(+) tumor-
inﬁltrating lymphocytes, consequently leading to inhibition
and diminution of tumor-inﬁltrating lymphocytes. Moreover,
we found a polarization to M2 macrophages, which may con-
tribute to the poor prognosis of DLBCL patients. Thus, tar-
geting of tumor cells and MDSCs using anti-PD-1/anti-PD-L1
or anti-CD33 antibodies might be a worthwhile new approach
to treat this aggressive form of cutaneous B-cell lymphoma.
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The transmembrane receptor “programmed death-1”(PD-1) belongs to the B7/CD28 family.1 PD-1 is ex-
pressed on the surface of activated T and B cells, follicular
helper T cells, dendritic cells (DCs), and monocytes.2,3 The
interaction between PD-1 and its ligand PD-L1 reduces T-
cell proliferation, cytokine release, and inhibits survival
proteins (eg, bcl-xl),4–7 which results in apoptosis.6,7 Phys-
iologically, PD-L1 is detected on monocytes, macrophages,
DCs, and regulatory T cells (Tregs).8 Many solid tumors
and Hodgkin lymphomas express PD-L1.9,10 In contrast,
PD-L1 is only rarely expressed by non-Hodgkin lympho-
mas, with the notable exceptions of nodal diﬀuse large B-cell
lymphoma (DLBCL) and virus-associated lymphoma.11–13
Some studies demonstrated that PD-L1 expressing tumor
cells can induce apoptosis in PD-1(+) tumor-inﬁltrating
lymphocytes (TILs).14,15 This might explain the poor prog-
nosis of patients suﬀering from tumors with high PD-L1
levels compared with those whose tumors show no or low
PD-L1 expression.16–18 Moreover, inhibition of the PD-1/
PD-L1 axis seems to be an eﬀective treatment against PD-
L1 expressing tumors.10,19
Primary cutaneous diﬀuse large B-cell lymphoma leg
type (pcDLBCL-LT) is listed in the revised version of
WHO classiﬁcation (2016) as a separate entity.20 It is
characterized by a distinct histologic and im-
munohistochemical proﬁle (bcl2+, bcl-6+/ , MUM-1+),
a typical clinical presentation with tumor nodules mostly
arising on the legs of elderly women and with a 5-year
survival time of <60%.21,22 In contrast, primary cutaneous
diﬀuse large B-cell lymphoma others (pcDLBCL-OT) refers
to rare cases of large B-cell lymphomas that do not belong
to the group of pcDLBCLs-LT or to the group of primary
cutaneous follicle center lymphomas.22
The composition and function of the tumor micro-
environment (TME) is one of the most important factors
for both tumor survival (immune escape) and antitumoral
defense. Major components of the TME comprise
TILs (especially Tregs),23,24 tumor-promoting M2
macrophages, tumor-suppressing M1 macrophages,25 and
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myeloid-derived suppressor cells (MDSCs).26 The data on
pathogenic and prognostic eﬀects of M2 macrophages in
nodal DLBCL are controversial.27–29 Nevertheless, Shen
et al30 demonstrated that the number of M2 macrophages
correlated negatively with prognosis in nodal DLBCL.
The aim of our study was to evaluate PD-1 and PD-




On the basis of established diagnostic criteria,20,21
biopsy specimens of 16 pcDLBCLs were investigated in-
dependently by 2 board-certiﬁed dermatopathologists
(W.K., C.M.). Thirteen of these cases were classiﬁed as
LT and 3 as OT. Fifteen samples were found to be ger-
minal center B cell like (GCB) or activated B cell like
(ABC) types according to Hans’ algorithm, which is
based on immunohistochemical expressions of CD10, bcl-
6, and MUM-1.31 Although it is known that these groups
do not exactly correspond to molecular categories, the
immunohistochemical algorithm has been recommended
by the current WHO classiﬁcation, due to gene expression
proﬁling still not being a routine test.20
Clinical information was obtained through retro-
spective review of the patients’ records, and communi-
cation with clinicians and patients. The patients’ data
were stored in a database. The Cantonal Ethics Com-
mittee of Zurich (No. 2014-0493) has approved the study.
Histology, Immunohistochemistry, and
Immunofluorescence
Biopsy specimens were ﬁxed in 10% buﬀered formalin,
embedded in paraﬃn, stained with hematoxylin and eosin
(H&E), and reviewed. The immunohistochemical studies
were conducted using the following antibodies: PD-1 (clone
MRQ-22, dilution RTU; CellMarque, Rocklin), PD-L1
(clone SP142, dilution 1:50; Roche, Mannheim, Deutschland),
CD33 (clone PWS44, dilution RTU; Leica Biosystems,
Muttenz, Switzerland), CD68 (clone PG-M1, dilution 1:100;
Dako, Glostrup, Denmark), and CD163 (clone 10D6,
dilution 1:400; Leica Biosystems). All immunohistochemical
stains were performed according to the manufacturer’s
protocol. Double stains were performed for PD-1/PD-L1,
PAX-5/PD-L1, and CD33/PD-L1. Immunoﬂuorescence
double stains for PAX-5/PD-L1 were added. Sections of hu-
man tonsils were used as positive controls.
Evaluation of the Slides
PD-L1, PD-1, and CD33 Expression by Tumor Cells
To investigate PD-L1 expression by the tumor cells,
double stainings with a nuclear B-cell marker (PAX-5)
were performed in all cases. Membrane-bound PD-L1
expression was examined for each sample by 1 inves-
tigator (C.M.), blinded to clinical data. As reported pre-
viously,4 5 high-power ﬁelds of representative tumor areas
were evaluated. The expression of PD-L1 on B cells was
veriﬁed by PAX-5 and PD-L1 double stains. The number
of double-expressing cells was given as a rate of all B cells.
The number of CD33(+) tumor cells was evaluated sim-
ilarly. PD-1 expression was investigated in a single stain.
Composition and Distribution of the TME
TILs. Owing to their characteristic morphology,
admixed TILs could be distinguished easily from macro-
phages, MDSCs, and tumor cells. The density of TILs ([0]
absent, [1] focal, [2] mild, [3] moderate, and [4] severe) and
their distribution pattern (peripheral vs. diﬀuse) were
evaluated in H&E.
PD-1 and PD-L1 Expressing Cells. The density ([1]
low, [2] intermediate, and [3] high) and the predominant
distribution (peripheral vs. diﬀuse) of PD-1 and PD-L1




























1 LT GCB 1 77 M 7.3 66 2
2 LT GCB 2 34 M 8 24.8 2
3 LT ABC 1 88 M 4.7 56 2
4 LT ABC 1 64 M 10 22 1
5 LT ABC 1 84 M 33.82 42.7 1
6 LT ABC 1 98 F 15.7 54 1
7 LT ABC 1 85 M 18.5 71.6 2
8 LT ABC 4 92 F 15.4 75.4 1
9 LT ABC NA 81 F 28.6 71.4 1
10 LT ABC 1 83 F 23.8 59.7 1
11 LT NA 1 91 F 14.9 68.1 2
12 LT ABC 1 82 M 23.6 22.3 1
13 LT ABC 1 90 M 44.8 78.4 2
14 OT ABC 1 97 F 17.2 60.7 2
15 OT GCB 3 79 M 27.5 88.6 2
16 OT GCB 1 92 M 25.2 65.1 2
NA indicates not applicable.
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expressing cells were evaluated. On the basis of PD-1/PD-
L1 double stainings, the number of PD-1/PD-L1 double-
expressing cells was given in percentage. The relation
between PD-1 and PD-L1 expression was noted.
MDSCs and Tumor-associated Macrophages. The
proportions and topographic distributions of CD33(+),
CD68(+), and CD163(+) cells were recorded in 5 repre-
sentative high-power ﬁelds. The number of PD-L1 ex-
pressing CD33(+) cells was evaluated in CD33/PD-L1
double stains and was depicted as a proportion of all
CD33(+) cells in percentage.
Statistical Analysis
All statistical analyses were performed using SPSS
22 (IBM, Hannover, Germany). A Mann-Whitney U test
was used to compare density and PD-1 expression of
TILs, and the number of macrophages in pcDLBCL-LT
versus pcDLBCL-OT. To assess inverse correlations of
PD-L1(+) tumor cells and PD-L1(+)/CD33(+) cells, we
calculated a 1-tailed Spearman correlation. A signiﬁcance
level P<0.05 was applied for all tests. The small sample
groups precluded statistical subgroup analyses (eg, of
pcDLBCL-LT ABC vs. GCB types).
RESULTS
Patients’ Characteristics and Histologic Findings
We investigated 16 biopsy specimens including 13
pcDLBCL-LT and 3 pcDLBCL-OT. Among pcDLBCL-
LT tumors, 10 cases were categorized as ABC type and 2
as GCB type, and in 1 case a subtyping could not be
performed, because there was not enough residual tumor
material. Among the pcDLBCL-OT, 1 ABC type and 2
GCB types were found.
The mean age of the patients in pcDLBCL-LT/
pcDLBCL-OT was 80.7/89 years, 9/2 were men and 4/1
FIGURE 1. PAX-5 (brown)/PD-L1 (red) double stains. A, Central tumor area: many tumor cells presented a PAX-5/PD-L1 (arrow)
double expression by immunohistochemistry. Inset: higher magnification of a PAX-5/PD-L1 double-expressing cell (arrow) (oil).
B, Immunofluorescence double stains: PAX-5 (red)/PD-L1 (green) double-expressing cells (arrow). C, Peripheral tumor areas:
tumor cells with PD-L1 double expression, next to a high number of PD-L1(+) PAX-5() (arrow) cells by immunohistochemistry.
Inset: higher magnification of a PD-L1(+) PAX-5() cell (arrow) (oil). D, Immunofluorescence PAX-5 (red)/PD-L1 (green). The arrow
indicates PD-L1 (green) positive cells, in which there were no B cells (Pax-5 negative).
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were women. Extracutaneous disease was excluded by
staging procedures according to international guidelines32
(detailed in Table 1).
Immunohistochemical Analysis
Expression in Healthy Control
As previously reported, expression of PD-1 was found
in activated T lymphocytes and follicular helper T cells.3,33
PD-L1 was expressed by macrophages and DCs.8 Tonsils
were used as external onslide positive controls.
PD-L1, PD-1, and CD33 Expression by Tumor Cells
Distinct membrane expression of PD-L1 by the tu-
mor cells was observed in all of our investigated samples.
The mean percentage of PD-L1 expressing tumor cells
(double staining with PAX-5: Figs. 1A, B) was 19.9% in
pcDLBCL (range, 4.7 to 44.8, ±10.7), 19.2% in LT
(range, 4.7 to 44.8, ±11.6), and 24.6% in OT (range,
17.2 to 27.5, ±5.4). In PAX-5/PD-L1 double stains, a
considerable number of PD-L1(+) and PAX-5() cells
were found, which were accentuated in 3 cases at the tu-
mor margins (Figs. 1C, D).
Among pcDLBCL-LT, the PD-L1 score was higher
in ABC-type tumors (21.9) compared with that in GCB-
type tumors (7.7). However, the small pcDLBCL-OT
sample size precluded statistical analyses.
In both groups, PD-1 expression was lacking on
most tumor cells. In pcDLBCL-LT, the tumor cells ex-
pressed CD33 in 10 of 13 samples (mean number of
positive tumor cells: 15%; range, 2% to 60%) (CD33/
PAX-5 double stain: Fig. 2). The mean number in tumors
of the GCB type was 7.5% in contrast to 13.2% in the
ABC group. About 5.7% (range, 2% to 10%) of
pcDLBCL-OT tumor cells expressed CD33. There was no
inverse correlation between the number of PD-L1(+) tu-
mor cells and the number of PD-L1(+)/CD33(+) cells
(P=0.0995, 1-tailed Spearman). For details see Table 1.
Composition and Distribution of the TME
TILs. The distribution of TILs was diﬀuse in all
cases, and their number was low (focal or mild) (Fig. 3A).
Seven pcDLBCL-LT samples presented a focal and 6 a
mild inﬁltrate. In pcDLBCL-OT, the inﬁltrate was mild in
all cases. We found no signiﬁcant diﬀerences between the
density of TILs in pcDLBCL-LT versus pcDLBCL-OT
(P=0.189, Mann-Whitney U test).
PD-1 and PD-L1 Expression. The relation between
PD-1 and PD-L1 was variable. In 5 cases of pcDLBCL-
LT the number of PD-L1-positive cells was higher than
the number of PD-1-positive cells. All of these cases were
ABC types. The PD-1 expression in TILs did not diﬀer
signiﬁcantly when LT and OT were compared, and it was
not inversely correlated with the number of PD-L1 ex-
pressing cells. PD-1/PD-L1 double expression was found
in 17% (range, 0% to 40%) of the immune cells. In 3
cases no double expression could be observed.
MDSCs and Tumor-associated Macrophages. The
distribution of the immune cells (without TILs) was
predominantly diﬀuse. In 3 cases of pcDLBCL-LT the
inﬁltrate was accentuated in the periphery of the tumor
cell conglomerates. The TME predominantly consisted of
CD163(+) M2 macrophages (Fig. 3B), whereas CD68(+)
macrophages were less numerous (Fig. 3D) (M1:M2=1:4
to 6) in all cases. Moreover, a high proportion of CD33(+)
MDSCs was interspersed, which coexpressed PD-L1 in
63% of the cells (Fig. 3C).
The number of MDSCs and the number of macro-
phages did not correlate with the diﬀerent subtypes of
pcDLBCL. For details see Table 1.
The composition of the TME is illustrated
in Figure 4.
DISCUSSION
Since the development of immune checkpoint in-
hibitors, such as PD-1-blocking antibodies, the expression
of its ligand PD-L1 has been studied in diﬀerent tumors.
Hodgkin lymphoma, for example, demonstrated high
levels of PD-L1 expression and an excellent response to
anti-PD-1 therapy.10 In non-Hodgkin lymphomas, PD-
L1 is only rarely expressed and conﬁned to a subset of
EBV-associated B-cell lymphomas and systemic
DLBCLs.13 In the latter, PD-L1 expression was reported
in 20% to 57% of cases, preferentially in the less favor-
able nodal DLBCL of the ABC type rather than that of
the GCB type.11–13 This discrepancy might be explained
by cytogenetic alterations as well as protein expression of
PD-L1/PD-L2, which is more frequent in the ABC sub-
type.34 pcDLBCLs have not been investigated so far. We
found PD-L1 expression in all of our samples, albeit to a
variable extent. Similar to the results in nodal DLBCL,11
FIGURE 2. PAX-5 (brown)/CD33 (red) double stain. Brown
nuclear staining of the tumor cells (PAX-5) surrounded by a
cytoplasmic red signal (CD33) (arrow) (oil). For comparison,
PAX-5(+) cells (brown) without cytoplasmic CD33 (red) were
marked by stars.
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we could ascertain in pcDLBCL-LT a higher number of
PD-L1 expressing tumor cells in the ABC-type than in the
GCB-type tumors. Gene expression proﬁle studies in
pcDLBCL-LT demonstrated that most samples were
similar to the ABC type of nodal DLBCL.35 In accord-
ance with these studies, most of our cases were classiﬁed
as ABC type.
PD-1 expressing activated T lymphocytes play an
important role in tumor defense,37 which can be inhibited
by PD-L1 expressing B-cell lymphomas.11 We recently
demonstrated a signiﬁcantly lower level of PD-1 ex-
pressing TILs in pcDLBCL-LT as compared with both
indolent primary cutaneous marginal zone lymphoma
and primary cutaneous follicle center lymphoma.33 Con-
sistent with our current data, it is reasonable to assume
that PD-L1 expressing tumor cells induce apoptosis in
PD-1(+) TILs and stop the attraction of additional im-
mune cells. This might, at least in part, explain the low
level of PD-1(+) TILs in pcDLBCL-LT. In contrast,
PD-L1 was not expressed in systemic marginal zone
lymphoma and follicle center lymphoma.12 In light of the
known functions of PD-1/PD-L136 together with our ex-
pression proﬁle, it is conceivable that the expression of
PD-1/PD-L1 will be a promising target in the therapy of
aggressive pcDLBCL.
Interestingly, even tumors with no or low PD-L1
expression by the tumor cells themselves can respond to
PD-1 inhibition.4,5,37 This is arguably due to a high number
of PD-L1(+) cells within the TME, which shields the tumor
against attacking TILs. Tregs, for example, can inhibit PD-
1-positive TILs38,39 through PD-L1 expression. In
pcDLBCL, we have conﬁrmed and extended previous re-
sults40 of low numbers of T cells in the TME. This ob-
servation is also in line with a previous report41 suggesting
that Tregs do not play a primary role in the micro-
environment of pcDLBCL. They found low numbers of
TILs in PD-L1-positive tumors and discussed that PD-1(+)
TILs are expected to be low in the ABC type and more
abundant in the GCB type, because in normal tissue PD-1 is
highly expressed in germinal center follicular helper T cells.
MDSCs are a heterogenous population of immature
myeloid cells, representing precursors of granulocytes,
FIGURE 3. Composition of the TME. A, H&E stain demonstrated the composition of the infiltrate and stresses on the difficulty of
differentiating tumor cells from macrophages and MDSCs. Only a very small number of TILs (arrow) was admixed. The micro-
environment predominately consists of CD163(+) M2 macrophages (B) and CD33(+) MDSCs, which presented in 63% a PD-L1
coexpression (C). D, The number of CD68(+) M1 macrophages was low.
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macrophages, and DCs. Human MDSCs are chara-
cterized as HLADR/lowCD11b+CD14CD15+CD33+
granulocytic origin (G-MDSC) and HLADR/lowCD11b+
CD14+CD15CD33+ monocytic origin (M-MDSC).42–44
In systemic DLBCL an enrichment of MDSC has been
described.45 In contrast to a predominance of G-MDSC
in solid tumors,46–48 in lymphomas both populations
(G-MDSC and M-MDSC) are increased and suppress
T-cell responses.48–51 Our data are in line with these
observations. We postulate that next to the PD-L1(+)
tumor cells themselves, PD-L1(+) MDSCs suppress T-cell
functions. Our study also opens up the possibility to target
MDSCs therapeutically. Humanized antibodies directed
against CD33, for example, can block MDSCs and were
already tested for the treatment of acute myeloid leuke-
mia.52 The expression of CD33 has never been reported
before in mature B-cell lymphomas and is an interesting
new ﬁnding. Therefore, an inhibition of CD33 can simul-
taneously also attack the tumor cells directly.
Studies of gene-expressing proﬁles in nodal DLBCL
have revealed a high number of M2 macrophages in the
TME.53,54 Macrophages can shift their functional phe-
notype depending on signals generated from tumor and
stromal cells. On the basis of their function, they can be
divided into M1 and M2 macrophages. M1 macrophages
are involved in inﬂammatory responses and antitumoral
defense.55 In contrast, M2 macrophages reduce in-
ﬂammation and have tumor-promoting eﬀects.55 High
numbers of M2 macrophages in nodal DLBCL were as-
sociated with a poor clinical outcome.30 We found a po-
larization to M2 macrophages in all of our pcDLBCL
cases. As previously reported,57 we hypothesized that the
shift toward M2 macrophages was induced by the tumor
cells or their microenvironment. Moreover, M2 macro-
phages and tumor cells can release cytokines (eg, IL-10
and TGF-b) that suppress T-cell functions directly or
indirectly through PD-L1 expression56 and can promote
the M2 polarization.57
In summary, tumor cells of pcDLBCL consistently
express PD-L1 and CD33. The TME consists predom-
inately of M2 macrophages. T cells and CD68(+) mac-
rophages are only a minor component. Admixed MDSCs
expressed PD-L1 in 63% of the cells. We postulate that
PD-L1(+) tumor cells/cells of the TME induce apoptosis
in PD-1(+) TILs, which might explain the lower level of
PD-1+ TILs in pcDLBCL. We postulate that PD-L1(+)
cells of the microenvironment shield the tumor against
attacking TILs. Therefore, direct inhibition of tumor cells
through PD-L1 and CD33 as well as inhibition of mi-
croenvironmental cells, especially MDSCs, are a new and
promising therapeutic option.
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